HSBC Turns More Bullish on Amgen (AMGN) into 2026

Amgen Inc. (NASDAQ:AMGN) is included among the 12 Best Dogs of the Dow to Invest in.

On December 8, HSBC lifted its price target on Amgen Inc. (NASDAQ:AMGN) to $425 from $381. The firm also retained a Buy rating. The call came as part of the firm’s 2026 outlook for the pharma sector. HSBC sees the group in a strong position heading into 2026, “even more so if AI panic kicks in.” While its top picks lean toward “growth bucket ideas,” the firm noted that “fallen angels and value could work as well.”

On December 11, Amgen Inc. (NASDAQ:AMGN) shared separate news. The U.S. Food and Drug Administration approved UPLIZNA for the treatment of generalized myasthenia gravis, or gMG. The decision gives patients a new targeted option that could offer long-term disease control with just two doses a year, following the initial loading doses.

Samantha Masterson, president and chief executive officer of the Myasthenia Gravis Foundation of America, made the following remark:

“Managing a rare and chronic illness can mean facing unpredictable relapsing symptoms and demanding treatment schedules. This approval marks an important milestone, offering durable efficacy and a dosing schedule that provides people living with generalized myasthenia gravis six months of treatment-free time between maintenance doses.”

gMG is a rare and unpredictable autoimmune condition driven by B cells. It disrupts communication between nerves and muscles, leading to fluctuating muscle weakness that can worsen without warning. In the US, myasthenia gravis affects an estimated 80,000 to 100,000 people.

Amgen Inc. (NASDAQ:AMGN) focuses on discovering, developing, manufacturing, and delivering innovative medicines, with an emphasis on biologics. Its work spans serious conditions including cancer, inflammation, heart disease, and rare disorders.

READ NEXT: 13 Best Blue Chip Stocks to Buy Under $50 and11 Best Low Priced Dividend Stocks to Buy According to Analysts.

Disclosure: None.